Skip to content
Yog Pharma
Gastrointestinal5-HT3 receptor antagonist

Ondansetron Hydrochloride is a 5-HT3 receptor antagonist indicated for prevention of nausea and vomiting from chemotherapy, radiotherapy and surgery. We supply it to US manufacturers of tablets, orally disintegrating tablets, oral solution and injection.

CAS103639-04-9365.9 g/molC18H24ClN3O3
2D structure of Ondansetron Hydrochloride, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 59774) and FDA’s substance registry

CAS number

103639-04-9

Molecular formula

C18H24ClN3O3

Molecular weight

365.9g/mol

FDA UNII

IUPAC name

9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride

InChIKey

VRSLTNZJOUZKLX-UHFFFAOYSA-N

Appearance
White to off-white powder.
Solubility
Soluble in water and in normal saline.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Supplied as the dihydrate. Say whether you need oral or injection grade. Ondansetron base, used in orally disintegrating tablets, is a separate API.

On the US market

Reference product
ZofranNDA 020007
Approved ANDAs
29 with a marketed product
Approved forms and strengths
  • Injection 2 mg/mL
  • Tablet 4 mg, 8 mg, 24 mg
  • Oral solution 4 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com